-
Skyhawk Shares A Closer Look at SKY-0515 Data, Plus A Peek At Expanding US Trial Access
Latest News
-
Huntington's disease therapeutics conference 2018 – day 1
Our daily roundup of the science presented at the 2018 HD Therapeutics Conference in Palm Springs
-
An early role for the Huntington's disease gene – but don't believe all the headlines
A surprising new paper sheds light on the role of the HD gene early in development. Should we worry?
-
New interest in an old target
Promising results in mice provide renewed optimism for mGluR5 antagonists
-
Ask the expert: Q&A on the huntingtin-lowering trial program
In a Q&A coordinated by the UK HD Association, Dr Ed Wild answers questions on the recently-announced trial
-
Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-
Switch off the genome editor when you’re done
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
-
A new way of thinking about trials to prevent Huntington's disease
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
-
New roles for huntingtin: removing a healthy protein to understand its function
Completely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests.
-
Precision huntingtin-lowering drug trials target the mutant protein
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-
A step forward for gene editing: CRISPR-Cas9 and HD
Evolving CRISPR-Cas9 techniques can now be used to edit the HD gene in a living mouse brain.
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
